The β-chemokines MIP-1α, MIP-1β and RANTES inhibit infection of CD4 + cells by primary,
non-syncytium-inducing (NSI) HIV-1 strains at the virus entry stage, and also block env-…

THE β-chemokine receptor CCR-5 is an essential co-factor for fusion of HIV-1 strains of the
non-syncytium-inducing (NSI) phenotype with CD4 + T-cells 1–5 . The primary binding site …

Eliciting broadly neutralizing antibodies to human immunodeficiency virus could bring
closer the goal of a successful AIDS vaccine. Here the International AIDS Vaccine Initiative …

For HIV-1 to enter a cell, its envelope protein (Env) must sequentially engage CD4 and a
chemokine coreceptor, triggering conformational changes in Env that ultimately lead to fusion …

The ability of antibodies to neutralize diverse primary isolates of human immunodeficiency
virus-type 1 in vitro has been questioned, with implications for the likely efficacy of vaccines. A …

We have isolated and characterized human monoclonal antibody 2G12 to the gp120 surface
glycoprotein of human immunodeficiency virus type 1 (HIV-1). This antibody potently and …

Antibodies capable of neutralizing HIV-1 often target variable regions 1 and 2 (V1V2) of the
HIV-1 envelope, but the mechanism of their elicitation has been unclear. Here we define the …

The identification and epitope mapping of broadly neutralizing anti-human immunodeficiency
virus type 1 (HIV-1) antibodies (Abs) is important for vaccine design, but, despite much …

The bicyclam AMD3100 (formula weight 830) blocks HIV-1 entry and membrane fusion via
the CXCR4 co-receptor, but not via CCR5. AMD3100 prevents monoclonal antibody 12G5 …

A desirable but as yet unachieved property of a human immunodeficiency virus type 1 (HIV-1)
vaccine candidate is the ability to induce broadly neutralizing antibodies (bNAbs). One …